Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab
暂无分享,去创建一个
L. Qin | C. Antonescu | J. Erinjeri | A. Shoushtari | W. Tap | M. Gounder | R. DeMatteo | P. Chi | R. Carvajal | N. Takebe | M. Dickson | M. Keohan | H. Streicher | Jennifer K. Loo | S. D’Angelo | M. Bluth | Zarine Patel | L. Gaffney | Lee Schneider | A. Sjoberg
[1] C. Antonescu,et al. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors , 2016, Clinical Cancer Research.
[2] S. D'Angelo,et al. Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028—A multicenter phase II study. , 2016 .
[3] Dafydd G. Thomas,et al. SARC009: Phase 2 study of dasatinib in patients with previously treated, high‐grade, advanced sarcoma , 2016, Cancer.
[4] D. Schadendorf,et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] F. Fulciniti,et al. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma , 2014, Cancer Immunology, Immunotherapy.
[6] L. Zitvogel,et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] J. Wolchok,et al. Pharmacodynamic effect of ipilimumab on absolute lymphocyte count (ALC) and association with overall survival in patients with advanced melanoma. , 2013 .
[8] J. Blay,et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.
[9] Eric C. Sorenson,et al. Imatinib Potentiates Anti-tumor T Cell Responses in Gastrointestinal Stromal Tumor through the Inhibition of Ido Nih Public Access Author Manuscript , 2022 .
[10] M. von Mehren,et al. A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] S. Mustjoki,et al. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. , 2010, Blood.
[12] N. S. Thomas,et al. Lck is a key target of imatinib and dasatinib in T-cell activation , 2010, Leukemia.
[13] D. Schadendorf,et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. , 2010, The Lancet. Oncology.
[14] A. Ray,et al. Signaling of c‐kit in dendritic cells influences adaptive immunity , 2010, Annals of the New York Academy of Sciences.
[15] M. Okada,et al. [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.
[16] Axel Hoos,et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.
[17] C. Divino,et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. , 2009, Cancer research.
[18] R. Grimer,et al. Management of Soft Tissue Sarcoma , 1990 .
[19] S. Mustjoki,et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy , 2008, Leukemia.
[20] Haesun Choi,et al. Response evaluation of gastrointestinal stromal tumors. , 2008, The oncologist.
[21] J. Crowley,et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] G. Rabinovich,et al. Immunosuppressive strategies that are mediated by tumor cells. , 2007, Annual review of immunology.
[23] Xin Huang,et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.
[24] Rossella Bertulli,et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial , 2004, The Lancet.
[25] J. Blay,et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. , 2004, The Journal of clinical investigation.
[26] A. D. Van den Abbeele,et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Samuel Singer,et al. PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.
[28] M. Fukayama,et al. C‐kit Gene Abnormalities in Gastrointestinal Stromal Tumors (Tumors of Interstitial Cells of Cajal) , 1999, Japanese journal of cancer research : Gann.
[29] Edvardsson,et al. Expression of c‐kit (CD117) and Ki67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumours , 1999, Histopathology.
[30] M. Brennan,et al. Management of soft tissue sarcoma , 1996, The British journal of surgery.
[31] D. Munn,et al. Immunology at the maternal-fetal interface: lessons for T cell tolerance and suppression. , 2000, Annual review of immunology.